Evaxion is pioneering in silico discovery
and development of vaccines and
antibodies with EDEN Technology
solving the challenge
of vaccine antigen discovery
Evaxion is building a unique pipeline
of prophylactic vaccines and
therapeutic antibodies against
serious infections diseases
EDEN Technology identifies novel antigens
in any bacterial pathogen
Evaxions’ lead vaccine against
S. aureus show unprecedented
results in preclinical development
providing significantly high
and broad protection
in different animal models
Evaxion Biotech is located at Copenhagen Bioscience Park, Denmark. Preclinical development is performed in collaboration with leading labs at medical schools in Copenhagen and Boston, USA.
Evaxion is building on a simple and scalable business model with manageable risk. Evaxion’s core capabilities are bioinformatics, early vaccine and antibody development and building alliances. Evaxion implemented an ambitious IP strategy and has already gained a strong IP position on vaccines and antibodies with a high unmet medical need.
Evaxion has a strong track record of collaborating with several leading human and veterinary vaccine companies. Evaxion is also collaborating with US academic and Government institutions and has gained support from Defence Advanced Research Project Agency (DARPA). Collaborations evolve around EDEN Technology with a focus on the development of novel vaccines against human and veterinary infectious diseases.
Evaxion Biotech is pioneering in silico discovery and the development of prophylactic vaccines and therapeutic antibodies. Based on our new ground-breaking in silico vaccine antigen discovery platform EDEN, Evaxion is able to identify novel antigens that elicit a highly cross-protective immune response, thereby overcoming the limitations of state-of-the-art vaccine discovery technologies. EDEN integrates big data, artificial intelligence and supercomputing in one platform, thereby enabling rapid and accurate discovery of novel antigens in any bacterial pathogen.
EDEN targets evasion strategies evolved over thousands of years by bacteria enabling Evaxion to defeat serious bacterial infections by bringing novel highly effective vaccines and antibodies to patients.
Tel: +45 31 26 26 15
Ole Maaloesvej 3
2200 Copenhagen N, Denmark
PLEASE CONTACT EVAXION BIOTECH
Sabine Molleskov Pedersen
© Copyright 2015 Evaxion Biotech All rights reserved